High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

doi:10.1016/j.jhep.2010.01.016

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Journal of hepatology - 1 Apr 2010

Wirth Stefan, Ribes-Koninckx Carmen, Calzado Maria Angeles, Bortolotti Flavia, Zancan Lucia, Jara Paloma, Shelton Mark, Kerkar Nanda, Galoppo Marcela, Pedreira Alejandra, Rodriguez-Baez Norberto, Ciocca Mirta, Lachaux Alain, Lacaille Florence, Lang Thomas, Kullmer Ulrike, Huber Wolf Dietrich, Gonzalez Teresita, Pollack Henry, Alonso Estella, Broue Pierre, Ramakrishna Jyoti, Neigut Deborah, Valle-Segarra Antonio Del, Hunter Bessie, Goodman Zachery, Xu Christine R, Zheng Hanzhe, Noviello Stephanie, Sniukiene Vilma, Brass Clifford, Albrecht Janice K

Abstract excerpt

BACKGROUND & AIMS: Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) is the standard of care for adults with chronic hepatitis C but was not approved for the treatment of children at the time of this study. The aim of this study was to evaluate the efficacy and safety of PEG-IFN alfa-2b...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Height

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Weight

Share to Child Development

Share to Drug Therapy, Combination

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 20189674
DOI: 10.1016/j.jhep.2010.01.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20189674-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.PMID 20189674Read ↗

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.Semantic proximity Read ↗

Treatment for chronic hepatitis C in children: a review.Semantic proximity Read ↗

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.Semantic proximity Read ↗

Treatment of hepatitis C in children: a systematic review.Semantic proximity Read ↗

Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.Semantic proximity Read ↗

Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.Semantic proximity Read ↗

Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation.Semantic proximity Read ↗

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.Semantic proximity Read ↗

Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C.Semantic proximity Read ↗

Hepatitis C virus in infants and children.Semantic proximity Read ↗

Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.